Stem Cell Stocks Sector Close-Up Trading August 7 2009: Aastrom Biosciences, Inc.(NasdaqCM: ASTM) trading up at $0.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
BUSINESS OF BIOTECHNOLOGY
They're perfecting scientific developments that could cure the world's toughest diseases, improve food production, and even yield energy alternatives. This is the exciting world of biotechnology, where young companies fight to make innovative discoveries -- and to find new and innovative ways of funding those innovations.
Business of Biotechnology is part of Business Exchange, suggested by
Arlene Weintraub.
This topic contains
1,248 news
and
4,696 blog
items.
Read updated news, blogs, and resources about Business of Biotechnology. Find user-submitted articles and reactions on Business of Biotechnology from
like-minded professionals.
Most Active
The most active stories in this topic based on user activity.
J&J and Amgen are among the companies that will have to revise product labels to reflect the risk.
The Israeli generic-drug maker has an ambitious growth strategy.
Chinese scientists have bred mice from cells that might offer an alternative to embryonic stem cells, producing the...
Jim Nelson says savvy investors can make huge profits in the first 100 days of the Obama presidency. Three sectors...
The European Patent Office (EPO) issued its final ruling last week rejecting a much-contested embryonic stem cell...
LONDON (Reuters) - The cost of specialty biotech drugs increased 8.7 percent last year in the United States, three...
A more recent addition to my transformational technologies portfolio, Medarex, has scored a huge win. The company,...
Biotech company Geron Corp. agreed to provide stem cells to General Electric Co.'s GE Healthcare for use in tools that...
The crop sprouting on his 150-acre farm in Calumet County is fortified with special traits at the microscopic level,...
The biotech giant is taken to task over its advertising brochure for kidney-disease drug Sensipar.
President Barack Obama on Monday welcomed the pharmaceutical industry's agreement to help close a gap in Medicare's...
A growing number of drug firms are trying their luck with social media tools such as Facebook and Twitter.
These top-rated IT workplaces combine choice benefits with hot technologies and on-target training.
Legislators in more than 20 states have questioned whether IMS has a constitutional right to collect prescription data.
Generic versions of expensive biotechnology drugs would reduce the amount of money spent on health care in the United...
The biotech giant is the subject of merger speculation, but CEO Jim Mullen says no such plans are underway.
The Cleveland Clinic doc is urging the federal government to back the creation of novel treatments.
The failure of a Merck drug to treat acute heart failure in a large clinical trial raises new questions about the...
Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of Wyeth (NYSE:WYE) and Merck & Co.'s (NYSE:MRK) $41 billion bid...
A spike in interest in the drug Zelnorm did little to boost prescriptions.
Shares in Dublin-based biotechnology company Elan Corp. (NYSE:ELN) surged Monday in London after The Wall Street...
The recession hasn't diminished Singapore's zeal to make the city a science and technology hub. The government has...
Despite a ban on direct-to-consumer drug advertising in their country, Canadians have been exposed to more than $90...
Top Sources: Business of Biotechnology
- investorideas.com
- bioedgeconsulting.com
- Biotech Blog
- bloomberg.com
- youtube.com
- News
- contrarianprofits.com
- Forbes.com
- industry.bnet.com
- Health Beat
account